pbs_code
stringclasses 390
values | drug
stringclasses 18
values | brand
stringclasses 32
values | formulation
stringclasses 38
values | indication
stringclasses 8
values | treatment_phase
stringclasses 57
values | streamlined_code
float64 9.19k
16.9k
⌀ | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | maximum_prescribable_pack
float64 1
5
| maximum_quantity_units
float64 1
180
| number_of_repeats
float64 0
6
| schedule_code
stringdate 2025-07-01 00:00:00
2025-08-01 00:00:00
| schedule_year
int64 2.03k
2.03k
| schedule_month
stringclasses 2
values |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9457R
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9457R
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9457R
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9457R
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9457R
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9457R
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9457R
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9457R
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9457R
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9457R
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9457R
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9457R
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9458T
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
First continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-08
| 2,025 |
AUGUST
|
9458T
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
First continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-08
| 2,025 |
AUGUST
|
9458T
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
First continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-08
| 2,025 |
AUGUST
|
9458T
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-08
| 2,025 |
AUGUST
|
9458T
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-08
| 2,025 |
AUGUST
|
9458T
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-08
| 2,025 |
AUGUST
|
9459W
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9459W
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9459W
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9459W
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9459W
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9459W
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9459W
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9459W
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9459W
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9459W
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9459W
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9459W
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-08
| 2,025 |
AUGUST
|
9460X
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
First continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-08
| 2,025 |
AUGUST
|
9460X
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
First continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-08
| 2,025 |
AUGUST
|
9460X
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
First continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-08
| 2,025 |
AUGUST
|
9460X
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
First continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-08
| 2,025 |
AUGUST
|
9460X
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
First continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-08
| 2,025 |
AUGUST
|
9460X
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
First continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-08
| 2,025 |
AUGUST
|
9615C
|
Etanercept
|
Enbrel
|
Injections 50 mg in 1 mL single use pre-filled syringes, 4
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9615C
|
Etanercept
|
Enbrel
|
Injections 50 mg in 1 mL single use pre-filled syringes, 4
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9615C
|
Etanercept
|
Enbrel
|
Injections 50 mg in 1 mL single use pre-filled syringes, 4
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9615C
|
Etanercept
|
Enbrel
|
Injections 50 mg in 1 mL single use pre-filled syringes, 4
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9621J
|
Abatacept
|
Orencia
|
Powder for I.V. infusion 250 mg
|
rheumatoid arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9621J
|
Abatacept
|
Orencia
|
Powder for I.V. infusion 250 mg
|
rheumatoid arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9621J
|
Abatacept
|
Orencia
|
Powder for I.V. infusion 250 mg
|
rheumatoid arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9621J
|
Abatacept
|
Orencia
|
Powder for I.V. infusion 250 mg
|
rheumatoid arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9621J
|
Abatacept
|
Orencia
|
Powder for I.V. infusion 250 mg
|
rheumatoid arthritis
|
First continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9621J
|
Abatacept
|
Orencia
|
Powder for I.V. infusion 250 mg
|
rheumatoid arthritis
|
First continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9641K
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9641K
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9641K
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9641K
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9641K
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9641K
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9641K
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9641K
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Private
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9657G
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
rheumatoid arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9657G
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
rheumatoid arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9657G
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
rheumatoid arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9657G
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
rheumatoid arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9657G
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
rheumatoid arthritis
|
First continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9657G
|
Tocilizumab
|
Actemra
|
Concentrate for injection 80 mg in 4 mL
|
rheumatoid arthritis
|
First continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9658H
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
rheumatoid arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9658H
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
rheumatoid arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9658H
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
rheumatoid arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9658H
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
rheumatoid arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9658H
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
rheumatoid arthritis
|
First continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9658H
|
Tocilizumab
|
Actemra
|
Concentrate for injection 200 mg in 10 mL
|
rheumatoid arthritis
|
First continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9659J
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
rheumatoid arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9659J
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
rheumatoid arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9659J
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
rheumatoid arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9659J
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
rheumatoid arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9659J
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
rheumatoid arthritis
|
First continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9659J
|
Tocilizumab
|
Actemra
|
Concentrate for injection 400 mg in 20 mL
|
rheumatoid arthritis
|
First continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-08
| 2,025 |
AUGUST
|
9662M
|
Adalimumab
|
Hadlima
|
Injection 40 mg in 0.8 mL pre-filled syringe
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9662M
|
Adalimumab
|
Amgevita
|
Injection 40 mg in 0.8 mL pre-filled syringe
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9662M
|
Adalimumab
|
Hyrimoz
|
Injection 40 mg in 0.8 mL pre-filled syringe
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9662M
|
Adalimumab
|
Abrilada
|
Injection 40 mg in 0.8 mL pre-filled syringe
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9662M
|
Adalimumab
|
Hadlima
|
Injection 40 mg in 0.8 mL pre-filled syringe
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9662M
|
Adalimumab
|
Amgevita
|
Injection 40 mg in 0.8 mL pre-filled syringe
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9662M
|
Adalimumab
|
Hyrimoz
|
Injection 40 mg in 0.8 mL pre-filled syringe
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9662M
|
Adalimumab
|
Abrilada
|
Injection 40 mg in 0.8 mL pre-filled syringe
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9662M
|
Adalimumab
|
Hadlima
|
Injection 40 mg in 0.8 mL pre-filled syringe
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9662M
|
Adalimumab
|
Amgevita
|
Injection 40 mg in 0.8 mL pre-filled syringe
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9662M
|
Adalimumab
|
Hyrimoz
|
Injection 40 mg in 0.8 mL pre-filled syringe
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9662M
|
Adalimumab
|
Abrilada
|
Injection 40 mg in 0.8 mL pre-filled syringe
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9662M
|
Adalimumab
|
Hadlima
|
Injection 40 mg in 0.8 mL pre-filled syringe
|
juvenile idiopathic arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9662M
|
Adalimumab
|
Amgevita
|
Injection 40 mg in 0.8 mL pre-filled syringe
|
juvenile idiopathic arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9662M
|
Adalimumab
|
Hyrimoz
|
Injection 40 mg in 0.8 mL pre-filled syringe
|
juvenile idiopathic arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9662M
|
Adalimumab
|
Abrilada
|
Injection 40 mg in 0.8 mL pre-filled syringe
|
juvenile idiopathic arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9663N
|
Adalimumab
|
Hyrimoz
|
Injection 40 mg in 0.8 mL pre-filled pen
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9663N
|
Adalimumab
|
Hadlima
|
Injection 40 mg in 0.8 mL pre-filled pen
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9663N
|
Adalimumab
|
Amgevita
|
Injection 40 mg in 0.8 mL pre-filled pen
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9663N
|
Adalimumab
|
Abrilada
|
Injection 40 mg in 0.8 mL pre-filled pen
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9663N
|
Adalimumab
|
Hyrimoz
|
Injection 40 mg in 0.8 mL pre-filled pen
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9663N
|
Adalimumab
|
Hadlima
|
Injection 40 mg in 0.8 mL pre-filled pen
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9663N
|
Adalimumab
|
Amgevita
|
Injection 40 mg in 0.8 mL pre-filled pen
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9663N
|
Adalimumab
|
Abrilada
|
Injection 40 mg in 0.8 mL pre-filled pen
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9663N
|
Adalimumab
|
Hyrimoz
|
Injection 40 mg in 0.8 mL pre-filled pen
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9663N
|
Adalimumab
|
Hadlima
|
Injection 40 mg in 0.8 mL pre-filled pen
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9663N
|
Adalimumab
|
Amgevita
|
Injection 40 mg in 0.8 mL pre-filled pen
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
9663N
|
Adalimumab
|
Abrilada
|
Injection 40 mg in 0.8 mL pre-filled pen
|
juvenile idiopathic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)
| null | true |
AUTHORITY_REQUIRED
|
Public
| 1 | 2 | 0 |
2025-08
| 2,025 |
AUGUST
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.